Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BKT14T00 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -1.28% 19.25 115,818 14:39:50
Bid Price Offer Price High Price Low Price Open Price
19.00 19.50 19.50 19.25 19.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.31 -10.92 -50.00 6
Last Trade Time Trade Type Trade Size Trade Price Currency
13:35:29 O 91,024 19.225 GBX

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
10/7/202013:42Midatech Pharma (MTPH) sees 10-fold increase1,099
10/6/202011:50 Midatech Pharma Plc8
30/4/201921:51Midatech Pharma (MTPH) One to Watch 2
03/1/201712:41Midatech Pharma PLC181
10/8/201608:55MTPH-

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:39:2819.2391,02417,499.36O
12:35:3119.0022,4354,262.65O
10:01:5019.231,340257.62O
09:34:3519.231,019195.90O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

DateSubject
16/7/2020
09:20
Midatech Pharma Daily Update: Midatech Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 19.50p.
Midatech Pharma Plc has a 4 week average price of 19.25p and a 12 week average price of 14.75p.
The 1 year high share price is 114p while the 1 year low share price is currently 1.90p.
There are currently 32,585,891 shares in issue and the average daily traded volume is 47,189 shares. The market capitalisation of Midatech Pharma Plc is £6,272,784.02.
09/6/2020
18:07
mubz: https://www.marketscreener.com/MIDATECH-PHARMA-PLC-19157045/news/Midatech-Pharma-Letter-to-Deyan-Spiridonov-re-Midatech-30744197/ What is interesting is that this chap at Paul Hasting law firm- Deyan P. Spiridonov is a member of the firm's Mergers & Acquisitions practice. So have Secura Bio done this in order to trash MTPH share price and then put in a hostile bid to takeover Please be advised that in the event that Secura Bio refuses to withdraw its purported termination notice, Midatech and Midatech Limited will vigorously pursue any and all available remedies, including claims for monetary damages based on Secura Bio's intentional wrongdoing. Midatech and Midatech Limited also reserve all rights in law and equity against Secura Bio and its agents, including, without limitation, the right to pursue tort claims (and a recovery of fees and costs in the UK) resulting from Secura Bio's intentional efforts to cause harm to and to adversely affect Midatech's market position.
19/5/2020
11:19
tomboyb: https://uk.advfn.com/stock-market/london/midatech-pharma-MTPH/share-news/Midatech-Pharma-PLC-Correction-UK-Placing-to-Rais/82488599
08/1/2020
11:43
jpuff: I've added a few more. Still in the red somewhat on these but the signs are much better now I feel. There must be a bit of a overhang to clear so I expect steady albeit unspectacular progress on the share price for now. Imho dyor
08/12/2019
22:02
kw9143: Cut & paste job from Riddier of LSE N.B --- Cut & paste job from Riddier of LSE The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases. Shares in issue : 470mln Market cap : £12mln Share price December 2019 : 2.5p Cash at June 2019 : increased by £6.70 million in the six months to 30 June . This resulted in a cash balance at the period end of £8.98 million. • February, signed first major licence deal, with Chinese specialty pharmaceutical group, China Medical System ("CMS") . CMS is listed on the Hong Kong Stock Exchange (HK:867) with a market capitalisation of approximately HK$18.40 billion (c. £1.797 billion) as at 28 January 2019. The CMS Group had revenues of RMB 5,348.8 million (c. £600.2 million) • Strategic investment in the Company by China Medical System ("CMS") and an associated party of CMS (A&B (HK) Company Ltd ("A&B")) of £8 million (gross proceeds) in aggregate, plus agreement to licence the Group's pipeline products in the Greater China Area and certain South East Asian countries. They hold 20% of the share register as of 5th Nov 2019. • 8th October RNS their dosing of patients for their Neuro cancer trials was completed and they go on to say "Following MTD201 dosing, all subjects enter a 63 day observation and sampling period. This data will then be analysed, with top line results expected by the end of 2019 or early in 2020." • $2mln placing 3.9p Nov 2019 through a direct offering of 3,000,000 of its American Depositary Shares ("ADSs") (each ADS representing 20 of the Company's ordinary shares.) And with warrants excercisable at 4.8p • Grant funded project €2.6mln announced Dec 5th - rose 40% from 2.7p to 3.9p but fell back due to the seller ( which i assume to be ex Woodford stock controlled by LinkFund) • "Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer" and later goes on to re-confirm "Orphan Drug Status for this ultra-rare disease was granted for MTX110 in the US this year providing for a potentially more rapid approval process" • Spanish Government loan to further support the Group's manufacturing scale-up capabilities. If successful, it is expected that the loan will cover up to 75% of the manufacturing scale-up cost of approximately €15 million. The outcome expected around end of H1 2019. • Efforts are ongoing to pursue out-licence opportunities that secure up-front payments, particularly for MTD201 and the Q-Sphera platform.m • Link fund have 16% ( 77,825,626) as of 30th Oct. This has created a drag on the share price since mid 2019 and is now 40% below the November • Volume accelerated last 2 days e.g 6mln Thursday and now 4.5mln Friday.
06/12/2019
09:36
pre: so just over 3 years ago the share price was over £3, this one is in bargain territory imv.
05/12/2019
22:20
sam_: From LSE board this evening: "I just saw the following on Stocktwits which is a US social media platform designed for sharing ideas between investors and traders. Someone on there emailed Tim Metcalfe (Investor Relations at Midatech Pharma) in regards to the share price reaction to the RNS and this was the respond received: " Hi Jeff Don’t worry, I share your frustrations! As well as being an adviser to the company, I am also a shareholder. The stock was up 45% in London in the hour after the announcement went out, an appropriate response in my view, only to close only 3% up following the Nasdaq trading and its obviously gone down further since London close. We live in interesting times and I unfortunately see on numerous occasions here where good news creates liquidity and the sellers take advantage, ultimately pushing the price down. This was very good news today and I will be looking in detail at what’s happened in the market and what, if anything, the company can do to address the issues. All I can do is thank you for your support and patience. Best regards Tim" Screenshot : www. i.imgur .com /MPpNsq5.png "
28/5/2019
13:52
ih_433513: Still they haven’t announced which option for MTD201 they are pursuing. With time and money being of the essence it really beggars belief that they are seemingly incapable of making up their minds in a timely fashion. It seems blatantly obvious to me that the differentiated approach is the way to go. No wonder the share price is slipping - we have a Board incapable of making vital decisions. We simply cannot afford further delays in this process or we’ll run out of money before the trial(s) have been completed. In God’s name get on with it.
05/4/2019
12:19
mam fach: Exactly. Think MTP recovered to be 22% up last night. This re-alignment of share price with MTP is a red herring. IMHO
18/3/2019
20:38
mam fach: Looks like MTP is coming down to align with MTPH. Was hoping the reverse might happen. Probably know next few weeks which way share price is going.
30/12/2015
09:57
hutch_pod: Did you see this from 17th? hTtp://seekingalpha.com/author/bart-van-velzen/comments High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term
Midatech Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
MTPH
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200716 14:20:47